Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

30-09-2019 | Urothelial cancer | Video | Article

Researcher comment: IMvigor130 trial of atezolizumab in advanced urothelial cancer

print
PRINT
insite
SEARCH

Enrique Grande tells us why the IMvigor130 data, although very promising, are not quite ready for translation to the clinic yet (1:43).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Related content

07-10-2019 | Urothelial cancer | Conference coverage | News

PFS boost with atezolizumab–chemotherapy in advanced urothelial carcinoma

29-06-2018 | Bladder cancer | News

EMA, FDA restrict use of PD-1 pathway inhibitors for bladder cancer

05-09-2018 | FDA | News

PD-L1 diagnostics approved for pembrolizumab, atezolizumab use in urothelial cancer

08-08-2019 | Urothelial cancer | News

Balance needed for short- vs long-term immunotherapy risks, benefits in mUC
Image Credits